Decoding AML: How Immunophenotyping Offers New Hope in Leukemia Detection
"New research unveils stable leukemia markers in AML patients with mutated NPM1, paving the way for more accurate and early detection of residual disease after treatment."
Acute myeloid leukemia (AML) is a devastating disease, and the risk of relapse after treatment is a major concern for patients and their families. Traditionally, doctors have relied on bone marrow evaluations to check for signs of remission, but these methods aren't always sensitive enough to catch lingering leukemia cells.
That's where multiparameter flow cytometry (MFC) comes in. MFC is a sophisticated technique that can detect leukemia-associated immunophenotypes (LAIPs) – unique markers on leukemia cells – even when they're present at very low levels. The problem is, these markers can change during and after treatment, making it difficult to track the disease effectively.
Now, a new study offers a promising solution, focusing on AML patients with a specific mutation called NPM1. Researchers have identified a consistent pattern of LAIPs in these patients, offering a more reliable way to detect residual disease and potentially improve treatment outcomes.
AML in the United States
The American Cancer Society estimates that about 22,720 people in the United States will be diagnosed with acute myeloid leukemia (AML) in 2026—12,160 males and 10,560 females—and about 11,500 will die from it (6,520 males and 4,980 females). Most cases are expected to occur in adults. SEER reports that AML death rates are higher among people aged 65 and older; across leukemia overall, age-adjusted new-case rates were stable from 2014–2023, while age-adjusted death rates fell by an average of 1.8% per year from 2015–2024.
Diagnosis and Residual-Disease Monitoring
AML is classically defined by at least 20% myeloblasts or myeloblast equivalents in peripheral blood or bone marrow, although genetic information has enabled recognition of distinct molecular subgroups. Measurable residual disease (MRD) describes leukemic cells remaining after treatment and can provide prognostic insights, but MRD-based monitoring and treatment strategies remain debated. Flow-cytometric MRD detection is limited by immunophenotypic variability, similarity to normal hematopoietic stem and progenitor cells, and the absence of stable leukemia-associated immunophenotypes. A 2023 review identifies next-generation sequencing and digital PCR as emerging tools for MRD monitoring.
A Changing Treatment Landscape
A 2021 review describes AML prognosis and management as evolving rapidly following Food and Drug Administration approval of nine agents for different AML indications. It reviews milestones in AML research and therapy, prognostic assessment, prediction of treatment outcomes, and supportive care. A separate 2025 historical review notes that AML has been described and studied by many medical professionals and researchers, with understanding developing over time.
Unlocking the Secrets of Mutated NPM1 in AML
The research, conducted by Yi Zhou and colleagues at the University of Washington, investigated the immunophenotypes of leukemic blasts in patients with AML or myelodysplastic syndrome with excess blasts (MDS-EB) who have mutated NPM1. This mutation is particularly significant, representing a large subtype of AML with similar disease mechanisms. The study aimed to identify common LAIP patterns in these patients and assess their stability after therapy.
- Myeloid blasts with mutated NPM1 exhibit a characteristic pattern of LAIPs, present in almost all cases at initial diagnosis and relapse, regardless of morphologic variations or other genetic factors.
- These myeloid blasts can be detected at a level of approximately 0.1% of total leukocytes in morphologic remission with high specificity.
- This characteristic pattern remains stable, allowing for sensitive and specific detection of AML/MDS with mutated NPM1 after therapy.
Flow Cytometry, PCR, and Phenotype Shifts
In AML with t(8;21)(q22;q22.1), a study compared flow cytometry with real-time quantitative PCR for MRD detection and described newly emerging abnormalities at follow-up as “immunophenotype shifts.” A separate validation study reports that multiparameter flow cytometry can assess MRD in up to 90% of AML patients, while noting challenges arising from the disease’s phenotypic heterogeneity. Earlier work also found leukemia-associated immunophenotypes—aberrant surface-marker expression—useful for MRD detection, but not without potential pitfalls.
Limits to Generalizing Detection Results
A paper titled “Generalization Failures in AI-Based Leukemia Detection” describes the need for rapid, accurate diagnosis of both acute lymphoblastic leukemia and AML, and notes the long-standing use of trained hematologists examining blood smears under microscopes. A 2025 AML update says that the disease is often fatal despite available treatments, while diagnosis, risk assessment, monitoring, and management have changed substantially over the past decade. A 2025 systematic review and meta-analysis specifically examines AI for detecting AML from microscopic blood images, underscoring that this is an actively reviewed application rather than a settled diagnostic replacement.
A New Era in AML Monitoring
This research marks a significant step forward in the way we monitor and manage AML, particularly in patients with mutated NPM1. The identification of stable and consistent LAIPs offers a more reliable and sensitive method for detecting measurable residual disease (MRD).
AI as an Adjunctive Diagnostic Approach
A systematic review published in 2022 examined deep-learning methods for automatic acute-leukemia classification and detection, using the PRISMA principle. A review of adjunctive AML diagnosis categorizes AI approaches into three data modalities: blood-smear image analysis, flow-cytometry data interpretation, and genetic-data modeling. The sources frame these methods as areas of research into adjunctive diagnosis; they do not establish that AI replaces existing diagnostic approaches.
Aggressive Disease and Treatment Challenges
A 2025 update describes AML as a bone-marrow stem-cell cancer that is often fatal despite available treatments. A review of therapeutic challenges characterizes AML as highly aggressive, with poor overall survival and high relapse rates. It identifies conventional “7+3” chemotherapy as the standard regimen and points to suboptimal pharmacokinetics and significant systemic toxicity as ongoing challenges to long-term disease control.
A Relapse Case
A 2021 NEJM case report describes a 49-year-old man whose AML relapsed 14 months after his initial diagnosis and treatment. The report notes that molecular genetic profiling was performed at relapse. The case illustrates an individual course of relapse, while the supplied excerpt does not provide further clinical details.
By incorporating this knowledge into clinical practice, healthcare professionals can potentially identify patients at high risk of relapse earlier and tailor treatment strategies accordingly. This could involve interventions such as additional chemotherapy, targeted therapies, or stem cell transplantation.
Ultimately, the goal is to improve long-term survival rates and quality of life for individuals battling AML. The ability to detect residual disease with greater precision is a crucial component of this effort, paving the way for a more personalized and effective approach to cancer care.